Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00014430 2013-03-14

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms

NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Phase 1 Completed

15 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

24 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Meningeal Carcinomatosis, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00022529 2013-01-25

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

28 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Clinical Trials

IPATHER

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

B-PRECISE-01

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Panther

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

THELMA

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Bevacizumab in Multiple Phase I Combinations

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Immunotherapy Vaccine and Herceptin in Breast Cancer

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors